Pharvaris N.V. PHVS
Set alert
33.53 USD 0.00 0.00%
At close · Nov 2
33.29 -0.24 -0.72%
After hours · Nov 2, 4:00 PM ET
32.90 Day range 34.21
21.02 52-week range 43.25
- YTD
- +20.83%
- 1 year
- +50.90%
- Open
- 33.68
- Prev close
- 33.53
- Mkt cap
- 2.35B
- Vol
- 633.06K
- Avg vol
- 807.98K
- EPS
- -3.06
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 32.90
- High
- 34.21
- Forward P/E
- -10.97
- Beta
- -2.52
- Short ratio
- 3.40
- Inst. own
- 93.42%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 11, 2026
- 50-d avg
- 33.66
- 200-d avg
- 31.00
- 1y target
- 57.63
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 57.63 +71.9% upside
Now 33.53
- Target (low)
- 40.99
- Target (mean)
- 57.63
- Target (high)
- 78.98
Ratings (0m) 14 14 buy · 0 hold · 0 sell
- Strong buy3
- Buy11
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 14
- 1 month ago 14
- 2 months ago 14
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.71909 | -0.80 – -0.67 | -0.60 | -19.9% | 0 | 0.0% | 11 |
| Next quarter | -0.77064 | -0.90 – -0.66 | -0.71 | -8.5% | 0 | 0.0% | 11 |
| Current year | -2.77 | -3.01 – -2.39 | -2.97 | +6.6% | 0 | 0.0% | 13 |
| Next year | -2.72 | -3.53 – -2.11 | -2.77 | +1.9% | 32.23M | 0.0% | 12 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 23, 2026 | B of A Securities | Upgrade | Neutral | Buy |
| Sep 10, 2026 | Guggenheim | Maintained | Buy | Buy |
| Sep 9, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Sep 9, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Sep 9, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Sep 9, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Sep 9, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| Sep 9, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Sep 8, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 8, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Aug 13, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 13, 2026 | Guggenheim | Maintained | Buy | Buy |
| Aug 13, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| Jul 15, 2026 | Wells Fargo | Initiated | — | Overweight |
| Jun 25, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| May 13, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| Apr 9, 2026 | Wolfe Research | Initiated | — | Outperform |
| Apr 7, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Apr 6, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Mar 9, 2026 | RBC Capital | Initiated | — | Outperform |
| Mar 3, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Dec 4, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Dec 4, 2025 | Guggenheim | Maintained | Buy | Buy |
| Dec 4, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |
| Dec 4, 2025 | B of A Securities | Maintained | Neutral | Neutral |
| Dec 3, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 14, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |
| Nov 13, 2025 | Wedbush | Maintained | Outperform | Outperform |
| Nov 13, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 15, 2025 | HC Wainwright & Co. | Initiated | — | Buy |